La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

TELA Bio Bilan de santé

Santé financière contrôle des critères 3/6

TELA Bio possède un total de capitaux propres de $2.9M et une dette totale de $40.8M, ce qui porte son ratio d'endettement à 1422.2%. Son actif total et son passif total sont $60.2M et de $57.3M.

Informations clés

1,422.2%

Ratio d'endettement

US$40.82m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$26.50m
Fonds propres	US$2.87m
Total du passif	US$57.33m
Total des actifs	US$60.20m

Mises à jour récentes de la santé financière

Recent updates

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

Aug 19

Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

Jul 03

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

May 29

TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

May 23

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 24

Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

Mar 08

TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

Oct 07

Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

Jul 31

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Oct 02

Tela Bio prices $32M common stock offering

Aug 16

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

May 12

TELA Bio - Follow Up With Management

Jan 14

Our First Look At TELA Bio

Nov 04

TELA Bio Plugging Away

Oct 25

TELA Bio (TELA) Investor Presentation - Slideshow

May 26

Bearish: Analysts Just Cut Their TELA Bio, Inc. (NASDAQ:TELA) Revenue and EPS estimates

Mar 30

Health Check: How Prudently Does TELA Bio (NASDAQ:TELA) Use Debt?

Feb 12

TELA Bio guides Q4 and FY20 revenue below consensus

Jan 14

TELA Bio EPS misses by $0.09, beats on revenue

Nov 11

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de TELA ( $51.1M ) dépassent ses passifs à court terme ( $15.0M ).

Passif à long terme: Les actifs à court terme de TELA ( $51.1M ) dépassent ses passifs à long terme ( $42.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de TELA ( 499% ) est considéré comme élevé.

Réduire la dette: TELA avait des capitaux propres négatifs il y a 5 ans, mais ils sont désormais positifs et se sont donc améliorés.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: TELA dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: TELA dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 13.4 % chaque année

TELA Bio Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

Health Check: How Prudently Does TELA Bio (NASDAQ:TELA) Use Debt?

Recent updates

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

TELA Bio, Inc. to Report Q2, 2024 Results on Aug 12, 2024

TELA Bio, Inc.(NasdaqGM:TELA) dropped from Russell Small Cap Completeness Index

Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

TELA Bio, Inc. Appoints Jeffrey Blizard to its Board of Directors

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

TELA Bio, Inc. Appoints Greg Firestone as Chief Commercial Officer

TELA Bio, Inc. Provides Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.63 loss in 1Q 2023)

TELA Bio, Inc. to Report Q1, 2024 Results on May 09, 2024

TELA Bio, Inc., Annual General Meeting, Jun 04, 2024

TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

TELA Bio, Inc. Announces U.S. Commercial Launch of LIQUIFIX

Full year 2023 earnings released: US$2.04 loss per share (vs US$2.72 loss in FY 2022)

Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

TELA Bio, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Consensus EPS estimates fall by 215%

TELA Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased by 18% to US$14.40

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

TELA Bio, Inc. to Report Q3, 2023 Results on Nov 09, 2023

TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc

TELA Bio, Inc. Announces U.S. Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Consensus EPS estimates upgraded to US$0.57 loss

Second quarter 2023 earnings: EPS exceeds analyst expectations

TELA Bio, Inc. Reaffirms Revenue Guidance for Full Year 2023

Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

TELA Bio, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Tela Bio, Inc. Reaffirms Earnings Guidance for the Full Year 2023

Insufficient new directors

Consensus EPS estimates fall by 13%, revenue upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

TELA Bio Announces U.S. Commercial Launch of NIVIS Fibrillar Collagen Pack

Price target decreased to US$17.40

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$17.40

TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022

TELA Bio, Inc. to Report Q3, 2022 Results on Nov 09, 2022

TELA Bio, Inc. Announces Publication of 24-Month Bravo Study Results Demonstrating Benefits of Ovitex(R) Reinforced Tissue Matrix in Hernia Repair

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Consensus forecasts updated

TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $32 million.

Tela Bio prices $32M common stock offering

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022

Tela Bio, Inc. Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs

TELA Bio, Inc. to Report Q2, 2022 Results on Aug 10, 2022

CFO & COO recently bought US$83k worth of stock

TELA Bio, Inc. Provides Revenue Guidance for the Fiscal Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

TELA Bio, Inc. Announces Revenue Guidance for the Full Year 2022

TELA Bio, Inc., Annual General Meeting, Jun 01, 2022

TELA Bio, Inc. Appoints Taylor Ocasio as General Counsel

TELA Bio, Inc. Announces U.S. Commercial Launch of SiteGuard™ No Rinse Antimicrobial Solution

TELA Bio - Follow Up With Management

High number of new directors

Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 3Q 2020)

Our First Look At TELA Bio

TELA Bio Plugging Away

TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique

Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 2Q 2020)

TELA Bio, Inc. Provides Earnings Guidance for the Full Year 2021

High number of new directors

TELA Bio, Inc.(NasdaqGM:TELA) dropped from Russell 3000E Index

Independent Director Adele Oliva has left the company

Chief Financial Officer Nora Brennan has left the company